Abstract
Myoclonic epilepsy is being increasingly recognized as a late onset complication in middle-aged or elderly patients with Down syndrome, in association with acute cognitive decline or dementia. We report a case of late onset myoclonic epilepsy in Down syndrome (LOMEDS) with acute cognitive decline, aged 45 year-olds. Although her intelligence condition remained poor with one to two-words sentences and difficult in following commands even after treatment, induction of levetiracetam and lamotorigin resulted in rapid, sustained seizure freedom and upgrading social activity with no adverse events. A combination of levetiracetam and lamotorigin appear to be effective for LOMEDS, and could be considered as first line agents for this special condition.
Original language | English |
---|---|
Pages (from-to) | 564-567 |
Number of pages | 4 |
Journal | Journal of the Japan Epilepsy Society |
Volume | 32 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2015 |
All Science Journal Classification (ASJC) codes
- Neurology
- Clinical Neurology